BR112016015105A8 - conjugados var2csa-droga - Google Patents
conjugados var2csa-drogaInfo
- Publication number
- BR112016015105A8 BR112016015105A8 BR112016015105A BR112016015105A BR112016015105A8 BR 112016015105 A8 BR112016015105 A8 BR 112016015105A8 BR 112016015105 A BR112016015105 A BR 112016015105A BR 112016015105 A BR112016015105 A BR 112016015105A BR 112016015105 A8 BR112016015105 A8 BR 112016015105A8
- Authority
- BR
- Brazil
- Prior art keywords
- var2csa
- drug conjugates
- conjugates
- drug
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361921242P | 2013-12-27 | 2013-12-27 | |
| US201462051899P | 2014-09-17 | 2014-09-17 | |
| US201462051886P | 2014-09-17 | 2014-09-17 | |
| PCT/CA2014/000919 WO2015095952A1 (en) | 2013-12-27 | 2014-12-29 | Var2csa-drug conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016015105A2 BR112016015105A2 (pt) | 2017-09-19 |
| BR112016015105A8 true BR112016015105A8 (pt) | 2018-04-24 |
Family
ID=53477241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016015105A BR112016015105A8 (pt) | 2013-12-27 | 2014-12-29 | conjugados var2csa-droga |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10675355B2 (enExample) |
| EP (1) | EP3087091B1 (enExample) |
| JP (1) | JP6615115B2 (enExample) |
| KR (1) | KR20160125361A (enExample) |
| CN (1) | CN106459162A (enExample) |
| AU (1) | AU2014373640B2 (enExample) |
| BR (1) | BR112016015105A8 (enExample) |
| CA (1) | CA2935064C (enExample) |
| MX (1) | MX2016008448A (enExample) |
| RU (1) | RU2714933C2 (enExample) |
| SG (1) | SG11201605260VA (enExample) |
| WO (1) | WO2015095952A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014228489B2 (en) * | 2013-03-15 | 2018-11-15 | Zymeworks Bc Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| BR112016015105A8 (pt) | 2013-12-27 | 2018-04-24 | Var2 Pharmaceuticals Aps | conjugados var2csa-droga |
| KR102384740B1 (ko) * | 2013-12-27 | 2022-04-07 | 자임워크스 인코포레이티드 | 약물 접합체를 위한 설폰아마이드-함유 연결 시스템 |
| RS62860B1 (sr) | 2014-09-17 | 2022-02-28 | Zymeworks Inc | Citotoksična i antimitotička jedinjenja, i postupci upotrebe istih |
| SG11201704976VA (en) | 2015-01-30 | 2017-07-28 | Sutro Biopharma Inc | Hemiasterlin derivatives for conjugation and therapy |
| WO2017137423A1 (en) * | 2016-02-08 | 2017-08-17 | Synaffix B.V. | Improved sulfamide linkers for use in bioconjugates |
| US11590239B2 (en) | 2016-02-08 | 2023-02-28 | Synaffix B.V. | Antibody-conjugates with improved therapeutic index for targeting CD30 tumours and method for improving therapeutic index of antibody-conjugates |
| WO2017137456A1 (en) * | 2016-02-08 | 2017-08-17 | Synaffix B.V. | Bioconjugates containing sulfamide linkers for use in treatment |
| GEP20207149B (en) | 2016-03-22 | 2020-09-10 | Merck Sharp & Dohme | Allosteric modulators of nicotinic acetylcholine receptors |
| US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
| CN106512022B (zh) * | 2016-10-12 | 2019-09-27 | 广东艾时代生物科技有限责任公司 | 羟基红花黄色素a-红细胞黏附硫酸软骨素a受体蛋白多肽复合物在制备抗肿瘤药物的应用 |
| CN111051329B (zh) | 2017-08-10 | 2024-07-30 | 住友制药株式会社 | 哈米特林衍生物及它们的抗体药物复合物 |
| FI3666787T3 (fi) | 2017-08-10 | 2024-03-15 | Sumitomo Pharma Co Ltd | Hemiasterliinijohdannaisen sisältäviä vasta-aine-lääkekonjugaatteja |
| CN108570118B (zh) * | 2017-10-17 | 2020-07-03 | 中国科学院深圳先进技术研究院 | 一种胎盘样硫酸软骨素a或其衍生物的亲和层析纯化方法 |
| GB2585607B (en) | 2017-11-29 | 2022-09-07 | Cas Lamvac Guangzhou Biomedical Tech Co Ltd | Chimeric antigen receptor and application thereof |
| JP7479302B2 (ja) | 2019-02-13 | 2024-05-08 | 住友ファーマ株式会社 | ヘミアスタリン誘導体とその抗体薬物複合体 |
| EP3925668A4 (en) | 2019-02-13 | 2022-11-09 | Sumitomo Pharma Co., Ltd. | HEMIASTERLINE DERIVATIVE WITH CYSTEINE RESIDUES |
| CN110124045A (zh) * | 2019-04-30 | 2019-08-16 | 云南大学 | 疟原虫var2csa蛋白在抗肿瘤药物中的应用 |
| CN113952467A (zh) * | 2020-07-21 | 2022-01-21 | 深圳先进技术研究院 | 一种子宫内膜异位症分子诊疗制剂及其制备方法和应用 |
| US20250066436A1 (en) | 2021-12-22 | 2025-02-27 | Royal College Of Surgeons In Ireland | A conjugate for use in localising a molecule to the vascular endothelium |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5137877B1 (en) | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US6569834B1 (en) | 1992-12-03 | 2003-05-27 | George R. Pettit | Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides |
| RU2132334C1 (ru) | 1992-12-16 | 1999-06-27 | Басф Акциенгезельшафт | Аналог долостатина |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| ES2233928T3 (es) | 1993-10-01 | 2005-06-16 | Teikoku Hormone Mfg. Co., Ltd. | Derivados de dolastatina. |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| GB9508195D0 (en) | 1995-04-20 | 1995-06-07 | Univ British Columbia | Novel biologically active compounds and compositions,their use and derivation |
| CA2225325A1 (en) * | 1997-12-19 | 1999-06-19 | The University Of British Columbia | Hemiasterlin analogs |
| US8097648B2 (en) | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20050171014A1 (en) | 2002-02-27 | 2005-08-04 | Government Of The United States Of America, Represented By The Secretary, Department Of Health | Conjugates of ligand linker and cytotoxic agent and related composition and methods of use |
| US7064211B2 (en) | 2002-03-22 | 2006-06-20 | Eisai Co., Ltd. | Hemiasterlin derivatives and uses thereof |
| KR101208266B1 (ko) | 2002-03-22 | 2012-12-05 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 헤미아스텔린 유도체 및 이의 용도 |
| US7211696B2 (en) | 2002-04-23 | 2007-05-01 | The Ohio State University | Antileishmanial dinitroaniline sulfanomides with activity against parasite tubulin |
| ITMI20021391A1 (it) | 2002-06-25 | 2003-12-29 | Nicox Sa | Nitroderivati di inibitori della cicloossigenasi-2 |
| JP4741838B2 (ja) | 2002-07-31 | 2011-08-10 | シアトル ジェネティクス，インコーポレーテッド | 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用 |
| CN1705639A (zh) | 2002-09-20 | 2005-12-07 | 惠氏控股公司 | 用于合成微管蛋白抑制剂的中间体的合成方法 |
| WO2004026293A2 (en) * | 2002-09-20 | 2004-04-01 | Wyeth Holdings Corporation | Hemiasterlin derivatives for treating resistant tumors |
| AU2003295808A1 (en) | 2002-11-21 | 2004-06-18 | Wyeth | Hemiasterlin affinity probes and their uses |
| US7390910B2 (en) | 2003-08-08 | 2008-06-24 | Wyeth | Compounds for treating tumors |
| US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| US20080255090A1 (en) | 2003-09-15 | 2008-10-16 | The University Of British Columbia | Ceratamines A and B, and Analogues, Syntheses and Pharmaceutical Compositions Thereof |
| EP1675465B1 (en) | 2003-10-22 | 2010-03-03 | The Johns Hopkins University | Improved combination bacteriolytic therapy for the treatment of tumors |
| CN104998273A (zh) | 2003-11-06 | 2015-10-28 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| US7078562B2 (en) | 2004-01-19 | 2006-07-18 | Mitsubishi Gas Chemical Company, Inc. | Adamantane derivatives and resin compositions using the same as raw material |
| KR20070053214A (ko) * | 2004-08-26 | 2007-05-23 | 니콜라스 피라말 인디아 리미티드 | 신규 생분해성 링커를 함유하는 프로드럭 |
| WO2006039652A2 (en) * | 2004-09-30 | 2006-04-13 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chondroitin sulfate a binding domains |
| CA2586909A1 (en) | 2004-11-12 | 2006-12-14 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
| CA2587589A1 (en) | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| CA2614436C (en) | 2005-07-07 | 2016-05-17 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| AU2008309589B2 (en) | 2007-10-10 | 2012-07-05 | Novartis Ag | Spiropyrrolidines and their use against HCV and HIV infection |
| WO2009059309A2 (en) | 2007-11-01 | 2009-05-07 | Panacea Pharmaceuticals, Inc. | Furin-cleavable peptide linkers for drug-ligand conjugates |
| RU2515063C9 (ru) | 2008-01-30 | 2014-08-10 | Пиерис АГ | Мутеины липокалина слезной жидкости, обладающие аффинностью к с-мет рецепторной тирозинкиназе человека, и способы их получения |
| EP2842575B1 (en) | 2008-03-18 | 2017-09-27 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
| DK2865387T3 (da) * | 2008-11-21 | 2019-08-26 | Univ Copenhagen | Forberedelse af en immunreaktion |
| US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| WO2011037192A1 (ja) | 2009-09-25 | 2011-03-31 | アステラス製薬株式会社 | 置換アミド化合物 |
| ES2528956T3 (es) | 2010-06-10 | 2015-02-13 | Seattle Genetics, Inc. | Nuevos derivados de auristatina y su uso |
| FR2963241B1 (fr) | 2010-07-30 | 2014-10-24 | Inst Rech Developpement Ird | Vaccin contre le paludisme gestationnel |
| PH12012500542A1 (en) | 2010-09-24 | 2012-11-12 | Astellas Pharma Inc | Substituted amide compound |
| JP5559439B2 (ja) | 2011-02-25 | 2014-07-23 | ロンザ リミテッド | タンパク質薬剤接合体のための分枝リンカー |
| WO2012123957A1 (en) | 2011-03-16 | 2012-09-20 | Council Of Scientific & Industrial Research | Oligopeptides and process for preparation thereof |
| AU2012236511B2 (en) | 2011-03-30 | 2016-04-28 | Arizona Board Of Regents, For And On Behalf Of, Arizona State University | Auristatin tyramine phosphate salts and auristatin aminoquinoline derivatives and prodrugs thereof |
| KR102023496B1 (ko) | 2011-04-21 | 2019-09-20 | 시애틀 지네틱스, 인크. | 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도 |
| US20130190248A1 (en) | 2011-07-26 | 2013-07-25 | Agensys, Inc. | Substituted peptide analogs |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| WO2013072813A2 (en) | 2011-11-17 | 2013-05-23 | Pfizer Inc. | Cytotoxic peptides and antibody drug conjugates thereof |
| PL2812024T3 (pl) * | 2012-02-09 | 2018-09-28 | Var2 Pharmaceuticals Aps | Celowanie glikanów siarczanu chondroityny |
| WO2013173391A1 (en) | 2012-05-15 | 2013-11-21 | Concortis Biosystems, Corp | Drug-conjugates, conjugation methods, and uses thereof |
| EP3536700A1 (en) | 2012-06-07 | 2019-09-11 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
| IL278638B1 (en) | 2012-06-19 | 2025-09-01 | Ambrx Inc | Anti-CD70 antibody drug conjugates |
| BR112014032346A2 (pt) | 2012-06-26 | 2017-06-27 | Del Mar Pharmaceuticals | métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes |
| JP6133431B2 (ja) | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
| MX379355B (es) | 2012-12-21 | 2025-03-11 | Altrubio Inc | Enlazadores autodestructivos hidrofilos y conjugados de los mismos. |
| ES2628156T3 (es) | 2013-02-14 | 2017-08-01 | Bristol-Myers Squibb Company | Compuestos de tubulisina, métodos para su fabricación y su uso |
| AU2014228489B2 (en) | 2013-03-15 | 2018-11-15 | Zymeworks Bc Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| CN106132431A (zh) | 2013-10-15 | 2016-11-16 | 索伦托治疗有限公司 | 具有靶向分子和两种不同药物的药物偶联物 |
| PL3082877T3 (pl) | 2013-12-17 | 2020-02-28 | Novartis Ag | Cytotoksyczne peptydy i ich koniugaty |
| BR112016015105A8 (pt) | 2013-12-27 | 2018-04-24 | Var2 Pharmaceuticals Aps | conjugados var2csa-droga |
| KR102384740B1 (ko) | 2013-12-27 | 2022-04-07 | 자임워크스 인코포레이티드 | 약물 접합체를 위한 설폰아마이드-함유 연결 시스템 |
| RS62860B1 (sr) | 2014-09-17 | 2022-02-28 | Zymeworks Inc | Citotoksična i antimitotička jedinjenja, i postupci upotrebe istih |
| US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
| US10975112B2 (en) | 2015-06-16 | 2021-04-13 | Hangzhou Dac Biotech Co., Ltd. | Linkers for conjugation of cell-binding molecules |
-
2014
- 2014-12-29 BR BR112016015105A patent/BR112016015105A8/pt not_active Application Discontinuation
- 2014-12-29 RU RU2016130348A patent/RU2714933C2/ru active
- 2014-12-29 SG SG11201605260VA patent/SG11201605260VA/en unknown
- 2014-12-29 JP JP2016561041A patent/JP6615115B2/ja active Active
- 2014-12-29 CN CN201480076448.XA patent/CN106459162A/zh active Pending
- 2014-12-29 AU AU2014373640A patent/AU2014373640B2/en active Active
- 2014-12-29 WO PCT/CA2014/000919 patent/WO2015095952A1/en not_active Ceased
- 2014-12-29 MX MX2016008448A patent/MX2016008448A/es unknown
- 2014-12-29 CA CA2935064A patent/CA2935064C/en active Active
- 2014-12-29 EP EP14874710.8A patent/EP3087091B1/en active Active
- 2014-12-29 US US15/108,258 patent/US10675355B2/en active Active
- 2014-12-29 KR KR1020167020681A patent/KR20160125361A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN106459162A (zh) | 2017-02-22 |
| RU2016130348A (ru) | 2018-01-31 |
| EP3087091B1 (en) | 2021-10-20 |
| US10675355B2 (en) | 2020-06-09 |
| JP2017505335A (ja) | 2017-02-16 |
| US20180117163A9 (en) | 2018-05-03 |
| AU2014373640B2 (en) | 2018-08-30 |
| MX2016008448A (es) | 2017-01-09 |
| KR20160125361A (ko) | 2016-10-31 |
| CA2935064A1 (en) | 2015-07-02 |
| RU2016130348A3 (enExample) | 2018-08-06 |
| CA2935064C (en) | 2023-06-27 |
| AU2014373640A1 (en) | 2016-07-07 |
| SG11201605260VA (en) | 2016-07-28 |
| BR112016015105A2 (pt) | 2017-09-19 |
| WO2015095952A1 (en) | 2015-07-02 |
| EP3087091A1 (en) | 2016-11-02 |
| JP6615115B2 (ja) | 2019-12-04 |
| US20170246310A1 (en) | 2017-08-31 |
| EP3087091A4 (en) | 2017-06-14 |
| RU2714933C2 (ru) | 2020-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301247I1 (nl) | Mirikizumab | |
| DK3460054T3 (da) | Histidyl-tRNA-syntetase-Fc-konjugater | |
| HRP20190056T1 (hr) | Konjugat anti-trop2 antitijelo-lijek | |
| DK3342773T3 (da) | Syk-hæmmere | |
| BR112016015105A8 (pt) | conjugados var2csa-droga | |
| DK3613453T3 (da) | Fordamper | |
| LT3003386T (lt) | Antikūno-vaisto konjugatai | |
| DK3077047T3 (da) | Aramcholsalte | |
| DK3052081T3 (da) | Pastil | |
| DK3060460T3 (da) | Saddel | |
| DK3027598T3 (da) | Oxoquinazolinyl-butanamidderivater | |
| DK2956698T5 (da) | Bindestrimler | |
| DK2946640T3 (da) | Langmuir-probe | |
| EP2943489A4 (en) | DEUTERATED MOMELOTINIB | |
| EP2991647A4 (en) | DEUTERED AMLEXANOX | |
| EP2853297A4 (en) | kendama | |
| DK3071227T3 (da) | Fiskevaccine | |
| DE112014001252A5 (de) | Aufbissschiene | |
| DK3086679T3 (da) | Sportssko | |
| DK2981168T3 (da) | Laminitiskile | |
| ES1078715Y (es) | Mosquitera | |
| FI10779U1 (fi) | Energiapuukoura | |
| DE112014005422A5 (de) | Friktionsfalschdrallaggregat | |
| BR112016000501A2 (pt) | Nalador | |
| FI10440U1 (fi) | Monikäyttösuutin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: C07K 14/445 (2006.01), A61K 47/00 (2006.01), A61P |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |